RxDoctor Payments Data

William Thornbury, MD

Family Medicine · Glasgow, KYNPI 1417027525

Payments from drug & device makers

$7,853in general payments, 2019–2025

Across 500 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$918
  • Novartis$802
  • AbbVie$481
  • Amgen$384
  • Bayer$384
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$7,80599%
  • Education$481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,853 in reported general payments places this provider in the 90th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$402,648
Medicare patients
450
Services billed
5,905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide222$239,796
OzempicSemaglutide161$197,954
EliquisApixaban245$136,961
FarxigaDapagliflozin Propanediol122$93,972
Trelegy ElliptaFluticasone/Umeclidin/Vilanter94$79,380
JardianceEmpagliflozin93$72,476
Xigduo XrDapaglifloz Propaned/Metformin99$69,441
TrulicityDulaglutide32$62,628
ProliaDenosumab33$56,938
TymlosAbaloparatide21$55,970
XareltoRivaroxaban56$47,104
JanuviaSitagliptin Phosphate48$42,747
MyrbetriqMirabegron111$40,201
VascepaIcosapent Ethyl50$26,932
EntrestoSacubitril/Valsartan32$25,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$294$302,424254 claims
Novo NordiskOzempic, Novolog Mix 70-30$918$205,595177 claims
PfizerEliquis$87$136,961245 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$1,067$123,495157 claims
GSKTrelegy Ellipta, Anoro Ellipta$324$88,239112 claims
Boehringer IngelheimJardiance, Synjardy$131$83,111105 claims
AmgenProlia$384$56,93833 claims
Radius Health, Inc.Tymlos$190$55,97021 claims
Johnson & JohnsonXarelto$238$47,10456 claims
MerckJanuvia$26$42,74748 claims
Astellas Pharma US IncMyrbetriq$26$40,201111 claims
NovartisEntresto$802$25,86132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Glasgow

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →